Dyslipidaemia and atherogenic risk in patients with systemic lupus erythematosus

Garrido, Jessica Roa; Alba, Hugo Alberto Radillo; Núñez, Éufrates Hernández; Olán, Francisco

doi:10.1016/j.medcle.2016.03.029

Cited by 5 publications

(10 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After this complex process, atherosclerosis development and cardiovascular disease risks increase in SLE patients [5,12,25]. In our study, we observed that cIMT and PAI values were higher in SLE patients compared to control individuals; there was a strong and independent relationship between cIMT and PAI, and these findings indicate that PAI can be used in the evaluation of subclinical atherosclerosis in SLE patients.…”

Section: Discussionsupporting

confidence: 60%

“…Gheito et al [24] demonstrated that cIMT levels were higher in SLE patients than in their control group and that it showed a correlation with SLEDAI. Batún Garrido et al [5] reported the strong correlation between SLE activity and dyslipidemia. They also showed the significant correlation between disease activity and PAI values.…”

Section: Discussionmentioning

confidence: 99%

“…Serum amyloid A, which is released from the liver and other tissues in response to cytokines, can lead to the replacement of amyloid A-1 with apoprotein A-1 and increase in the HDL clearance [16]. As a result of these effects, elevated TG levels increase the hepatic very-low-density lipoprotein production, and decrease in the TG rich lipoprotein clearance and decrease in serum HDL levels can be observed [5,12].…”

Section: Discussionmentioning

confidence: 99%

“…Atheroma, which develops due to the accumulation of the cholesterol crystals in the inner layers of the atherosclerotic arteries, causes the narrowing and blockage of the lumen. Systemic inflammation, increased oxidative stress, and alteration in the lipid profile are important in the development and the progression of the process [5,10,18]. There are studies in which the TG and HDL and the ratio of TG and HDL can be used to calculate the PAI.…”

Section: Discussionmentioning

confidence: 99%

“…In this context, a high atherogenic index (TG-HDL ratio) was demonstrated in SLE patients [5]. However, plasma atherogenic index (PAI) has been measured using a different method that it is obtained using the logarithmic transformation of the TG-HDL ratio and can be efficiently used to determine the cardiac risk and atherosclerosis [6,7].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Plasma Atherogenic Index is an Independent Indicator of Subclinical Atherosclerosis in Systemic Lupus Erythematosus

et al. 2017

View full text Add to dashboard Cite

Objective: Systemic lupus erythematosus (SLE) is characterized by chronic inflammation. Plasma atherogenic index (PAI) is a valuable marker for the cardiovascular disease and cardiac risk. The aim of this study was to evaluate the role and clinical use of PAI in atherosclerosis and the cardiac risk in SLE patients. Materials and Methods:We included 56 female SLE patients who were selected according to the American College of Rheumatology (1997) diagnosis criteria. Furthermore, we selected age-and body mass index (BMI)-matched 56 female healthy individuals. PAI was measured as a logarithmic value of triglyceride to high-density cholesterol ratio. We used carotid intima media thickness (cIMT) as an inflammatory marker because of its widespread use. The lipid and other biochemical parameters of patient and control groups were examined.Results: The PAI and cIMT values of SLE patients were 0.04±0.23 and 0.78±0.18 mm, respectively. Besides, for the control group, the PAI value was −0.09±0.20 and cIMT value was 0.50±0.15 mm (p=0.002, p<0.001; respectively). There was a strong correlation between cIMT and PAI (r=0.273, p=0.003). According to the multiple logistic regression analysis, we found that PAI value is an independent factor for cIMT in SLE patients (odds ratio: 2.6, 95 % confidence interval; 1.506-4.374; p=0.029). Conclusions:We determined that PAI can be used as an independent indicator for subclinical atherosclerosis in SLE patients.Keywords: Plasma atherogenic index, carotid intima-media thickness, systemic lupus erythematosus, atherosclerosis ÖZ Amaç: Sistemik lupus eritematozus (SLE), kronik inflamasyon ile karakterize bir hastalıktır. Plazma aterojenik indeks (PAI), kardiyovasküler hastalık ve kardiyak risk için değerli bir belirteçtir. Bu çalışmanın amacı PAI'in SLE hastalarında aterosklerozu ve kardiyak riski değerlendirmekteki rolü ve klinik kullanılabilirliliğini araştırmaktır.Gereç ve Yöntem: Amerikan Romatoloji Koleji (1997) tanı kriterlerine göre değerlendirilen 56 kadın SLE hastası dahil edildi. Ayrıca yaş ve vucüt kitle indeksi uyumlu 56 kadın sağlıklı kişi seçildi. PAI, trigliserit'in yüksek yoğunluklu kolesterole oranı logartimik ölçümüdür. Karotis intima medya kalınlığı (KIMK) inflamatuvar belirteç olarak yaygın olarak kullanıldığından, bu işareti bu çalışmada kullandık. Hasta ve kontrol gruplarının lipid ve diğer biyokimyasal parametreleri incelendi.Bulgular: Hasta grubunda PAI 0,04±0,23, KIMK 0,78±0,18 mm, kontrol grubunda PAI -0,09±0,20, KIMK 0,50±0,15 mm olduğu tespit edildi. Hasta grubunda PAI ve KIMK'ın kontrol grubuna kıyasla yüksek olduğu görüldü (sırasıyla p=0,002, p<0,001). SLE hastaları içerisine KIMK ile PAI arasında pozitif korelasyon olduğu görüldü (r=0,273, p=0,003). Multipl logistik regresyon analize göre PAI, KIMK için bağımsız risk faktörü olarak değerlendirildi (Olasılık oranı: 2,6, Güven aralığı %95 1,506-4,374, p=0,029).Sonuç: Bu çalışma bize PAI'nın SLE hastalarında subklinik aterosklerozun değerlendirilmesinde kullanılabilecek bağımsız bir belirteç olabileceğini d...

show abstract

Section: Discussionsupporting

confidence: 60%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Plasma Atherogenic Index is an Independent Indicator of Subclinical Atherosclerosis in Systemic Lupus Erythematosus

et al. 2017

View full text Add to dashboard Cite

show abstract

Dysregulated serum lipid profile and its correlation to disease activity in young female adults diagnosed with systemic lupus erythematosus: a cross-sectional study

2020

View full text Add to dashboard Cite

Background: Recent studies showed that dyslipidemia could be a critical factor in the progression of cardiovascular disease in systemic lupus erythematosus (SLE). The aim of the present study was to describe the relationship between serum lipid profile and SLE disease activity in young female adults with SLE. Methods: Seventy-one female subjects diagnosed with SLE aged 20~30 years were enrolled. Serum lipid profile including TC, TG, HDL-C, LDL-C, VLDL-C, Apo A, Apo B, and Apo E were evaluated between control and young female SLE patients. Univariate correlation analyses were performed to explore the correlation between serum lipid levels and SLE disease activity. Results: Our results showed that TG and VLDL-C levels were significantly increased in young female SLE as compared to control, with TC, HDL-C, LDL-C, Apo A, and Apo B significantly reduced. Meanwhile, univariate correlation analyses showed negative correlations between SLE disease activity index and HDL-C, LDL-C, Apo A, and Apo B; with positive correlations between SLE disease activity index and TG and VLDL-C. Conclusion: Serum lipid profile was significantly dysregulated in young female SLE patients. Moreover, SLE disease activity was correlated to the serum lipid levels, supporting the notion that the young patients with SLE might also have a higher risk of cardiovascular disease.

show abstract

Anti-Phosphatidylethanolamine and Anti-Phosphatidylserine Antibodies—Association with Renal Involvement, Atherosclerosis, Cardiovascular Manifestations, Raynaud Phenomenon and Disease Activity in Polish Patients with Systemic Lupus Erythematosus

et al. 2022

View full text Add to dashboard Cite

Objective. To evaluate the association between anti-phosphatidylethanolamine (aPE) and anti-phosphatidylserine (aPS) antibodies and cardiovascular risk, organ involvement and disease activity in systemic lupus erythematosus (SLE) patients. Methods. We studied 93 SLE patients and 30 controls. We analyzed levels of anti-phospholipid antibodies, including aPS and aPE, the profiles of antinuclear, anti-neutrophil cytoplasmic (ANCA) and anti-endothelial antibodies, carotid intima-media thickness (cITM) and atherosclerotic plaque presence, ankle-brachial and high resistance indices, atherosclerotic risk factors, organ manifestations and treatment. Results. Levels of aPS and aPE were significantly higher in SLE patients in comparison with the controls (p = 0.038 and p = 0.044, respectively). aPS was associated with the risk of Raynaud’s phenomenon (p = 0.021) development. aPE increased the risk of renal involvement (p = 0.049), cerebral stroke (p = 0.050), high vlues of cIMT (p = 0.041) development as well as occurrence of selected serological markers associated with activity of the disease such as anti-double stranded DNA (p = 0.021). The long duration of regular smoking (p = 0.021) and the high number of cigarettes/day (p = 0.015) were significantly associated with the risk of aPE occurrence. Conclusions. Patients with aPS and aPE are at risk of vascular involvement. Especially the presence of aPE may significantly increase the risk of thrombotic complications development in SLE patients without classical serological markers of APS. Finally, aPE might be used as a marker of disease activity and risk of renal injury development in this patient group. The classical atherosclerotic markers including lipid indices play an important role in complex analysis of cardiovascular risk in lupus patients and enable to identify patients at the highest risk and implement effective preventive, diagnostic and therapeutic procedures.

show abstract

Dyslipidaemia and atherogenic risk in patients with systemic lupus erythematosus

Cited by 5 publications

References 9 publications

Plasma Atherogenic Index is an Independent Indicator of Subclinical Atherosclerosis in Systemic Lupus Erythematosus

Plasma Atherogenic Index is an Independent Indicator of Subclinical Atherosclerosis in Systemic Lupus Erythematosus

Dysregulated serum lipid profile and its correlation to disease activity in young female adults diagnosed with systemic lupus erythematosus: a cross-sectional study

Anti-Phosphatidylethanolamine and Anti-Phosphatidylserine Antibodies—Association with Renal Involvement, Atherosclerosis, Cardiovascular Manifestations, Raynaud Phenomenon and Disease Activity in Polish Patients with Systemic Lupus Erythematosus

Contact Info

Product

Resources

About